Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

17.58
+0.58003.41%
Post-market: 17.730.1500+0.85%16:15 EDT
Volume:1.95M
Turnover:34.32M
Market Cap:3.42B
PE:-35.11
High:17.85
Open:17.38
Low:17.30
Close:17.00
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:0.60
T/O Rate:2.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:2.78
PE(LYR):-10.85

Loading ...

BUZZ-Legend Biotech slides on $226 mln share sale

Reuters
·
Jun 18

BRIEF-Legend Biotech Corporation Announces Pricing Of Public Offering

Reuters
·
Jun 18

Legend Biotech - Gross Proceeds From Offering Expected to Be About $226 Mln

THOMSON REUTERS
·
Jun 18

Legend Biotech - Prices 7.7 Mln Ads Public Offering at $29.35 per Ads

THOMSON REUTERS
·
Jun 18

Stocks to Watch: Smith & Wesson, Logistic Properties of the Americas, Legend Biotech

Dow Jones
·
Jun 18

Legend Biotech ADSs Fall After Company Announces Public Offering

Dow Jones
·
Jun 18

Legend Biotech secondary offering; price range $29.35-$31.35

TIPRANKS
·
Jun 18

Legend Biotech launches USD 225 million ADS follow-on offering

Reuters
·
Jun 18

Legend Biotech Corporation Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 18

Legend Biotech - Commences $225 Mln Public Offering of American Depositary Shares

THOMSON REUTERS
·
Jun 18

Legend Biotech management to meet with Oppenehimer

TIPRANKS
·
Jun 17

Legend Biotech Unveils Strong First-in-Human Data for In Vivo CAR-T LB2501 at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech says Phase 1 LB2501 in vivo CD19/CD20 CAR-T posts 100% ORR at higher dose in R/R B-cell NHL

Reuters
·
Jun 15

Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma

MT Newswires Live
·
Jun 15

Genscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company

Stock News
·
Jun 15

Legend Biotech announces first clinical proof-of-concept data for LB2501

TIPRANKS
·
Jun 15

GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma

TIPRANKS
·
Jun 14

Legend Biotech says Phase 1 trial shows 100% response rate at higher dose for in vivo CAR-T LB2501 in R/R B-NHL

Reuters
·
Jun 14

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Oncology Deal Shock Creates Three Very Different Stock Setups

Simply Wall St.
·
Jun 09